PRAXIS PRECISION MEDICINES, INC. Operating Cash Flow
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Operating Cash Flow of -$163.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$77.54M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$86.15M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$76.33M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$65.06M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$249.07M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$131.76M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$111.14M.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$185.04M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$77.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$163.69M 10-Q · filed 2026-08-06 | -$240.02M derived: sum of 3 quarters · filed 2026-08-06 | -$305.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$86.15M 10-Q · filed 2026-05-07 | -$162.48M derived: sum of 2 quarters · filed 2026-05-07 | -$227.53M derived: sum of 3 quarters · filed 2026-05-07 | -$282.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$76.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$141.38M derived: sum of 2 quarters · filed 2026-02-19 | -$196.06M derived: sum of 3 quarters · filed 2026-08-06 | -$249.07M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$65.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$119.73M derived: sum of 2 quarters · filed 2026-08-06 | -$172.74M 10-Q · filed 2025-11-05 | -$228.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$54.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$107.69M 10-Q · filed 2026-08-06 | -$163.81M derived: sum of 3 quarters · filed 2026-08-06 | -$191.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$53.01M 10-Q · filed 2026-05-07 | -$109.13M derived: sum of 2 quarters · filed 2026-05-07 | -$136.63M derived: sum of 3 quarters · filed 2026-05-07 | -$163.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$56.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$83.62M derived: sum of 2 quarters · filed 2026-02-19 | -$110.90M derived: sum of 3 quarters · filed 2026-02-19 | -$131.76M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$27.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$54.78M derived: sum of 2 quarters · filed 2025-11-05 | -$75.64M 10-Q · filed 2025-11-05 | -$99.50M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$27.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$48.13M 10-Q · filed 2025-08-04 | -$72.00M derived: sum of 3 quarters · filed 2026-02-19 | -$95.21M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$20.86M 10-Q · filed 2025-05-02 | -$44.72M derived: sum of 2 quarters · filed 2026-02-19 | -$67.93M derived: sum of 3 quarters · filed 2026-02-19 | -$99.15M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$23.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$47.08M derived: sum of 2 quarters · filed 2026-02-19 | -$78.29M derived: sum of 3 quarters · filed 2026-02-19 | -$111.14M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$23.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$54.43M derived: sum of 2 quarters · filed 2024-11-06 | -$87.28M 10-Q · filed 2024-11-06 | -$116.08M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$31.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$64.06M 10-Q · filed 2024-08-13 | -$92.87M derived: sum of 3 quarters · filed 2024-08-13 | -$137.78M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$32.85M 10-Q · filed 2024-05-13 | -$61.65M derived: sum of 2 quarters · filed 2024-05-13 | -$106.57M derived: sum of 3 quarters · filed 2024-05-13 | -$163.78M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$28.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$73.72M derived: sum of 2 quarters · filed 2024-03-05 | -$130.93M derived: sum of 3 quarters · filed 2024-03-05 | -$185.04M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$44.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$102.13M derived: sum of 2 quarters · filed 2023-11-07 | -$156.24M 10-Q · filed 2023-11-07 | -$201.09M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$57.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$111.32M 10-Q · filed 2023-08-09 | -$156.18M derived: sum of 3 quarters · filed 2023-08-09 | -$180.14M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$54.11M 10-Q · filed 2023-05-11 | -$98.97M derived: sum of 2 quarters · filed 2023-05-11 | -$122.93M derived: sum of 3 quarters · filed 2023-05-11 | -$152.94M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$44.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | -$68.82M derived: sum of 2 quarters · filed 2023-02-07 | -$98.83M derived: sum of 3 quarters · filed 2023-02-07 | -$124.55M 10-K · filed 2023-02-07 |
| 2021-09-30 | -$23.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$53.98M derived: sum of 2 quarters · filed 2022-11-09 | -$79.70M 10-Q · filed 2022-11-09 | -$99.92M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$30.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$55.73M 10-Q · filed 2022-08-08 | -$75.96M derived: sum of 3 quarters · filed 2022-08-08 | -$89.84M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$25.72M 10-Q · filed 2022-05-09 | -$45.95M derived: sum of 2 quarters · filed 2022-05-09 | -$59.83M derived: sum of 3 quarters · filed 2022-05-09 | -$69.78M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$20.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$34.11M derived: sum of 2 quarters · filed 2022-02-28 | -$44.05M derived: sum of 3 quarters · filed 2022-02-28 | -$52.62M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$13.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$23.83M derived: sum of 2 quarters · filed 2021-11-03 | -$32.40M 10-Q · filed 2021-11-03 | -$42.35M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$9.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$18.51M 10-Q · filed 2021-08-16 | -$28.47M derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | -$8.57M 10-Q · filed 2021-05-11 | -$18.52M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$9.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$33.42M 10-K · filed 2021-03-17 | ||
| 2019-09-30 | -$23.47M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |